Anti-Y. pestis Fraction 1 antigen Recombinant Antibody (F1-04-A-G1) (MRO-145MZ) (CAT#: MRO-145MZ)

Figure 1 MAb 7.3 and F1-04-AG-1 display synergy when administered postinfection.

Mice were challenged s.c. with 91 MLD of Y. pestis and treated 48 h after plague challenge with MAb 7.3 (35 μg) or F1-04-A-G1 (100 μg) individually or together. Deaths were recorded over a 14-day period.

Synergistic Protection of Mice against Plague with Monoclonal Antibodies Specific for the F1 and V Antigens of Yersinia pestis

Figure 2 Specific binding of the human anti-F1 IgG1 to the Y. pestis cell surface was detected by a flow cytometry assay.

Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague Model

Figure 3 Serum concentrations of human and mouse anti-F1 and anti-V mAbs in the plague mouse model over time.

The same amount of human IgGs (500 µg) as used in the challenge studies were administered via i.p. and blood samples were collected at indicated time points. The human IgG concentration was determined by ELISA. The data shown are averages from three mice for each IgG. A. The amount of remaining human anti-F1 m252 and anti-V m254 in mouse serum. B. The amount of remaining mouse anti-F1 F1m and anti-V 7.3m in mouse serum.

Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague Model

Figure 4 Epitope binding analysis of human Fab by competition-ELISA.

Lack of competition between human Fab anti-F1 fragment and mouse anti-F1(F1m) mAb.

Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague Model

Figure 5 Immunofluorescence detection of human anti-F1 IgG1 mAb (m252) binding to the Y. pestis cell surface.

The mouse anti-F1 mAb (F1m) was used as a positive control.

Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague Model